Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity-Reference-Cited by-同舟云学术

Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity

Published:2019-11-25 Issue:22 Volume:3 Page:3688-3699
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Schramm Franziska¹,zur Stadt Udo¹,Zimmermann Martin²,Jorch Norbert³,Pekrun Arnulf⁴,Borkhardt Arndt⁵,Imschweiler Thomas⁶,Christiansen Holger⁷,Faber Jörg⁸,Schmid Irene⁹,Feuchtinger Tobias⁹^ORCID,Beron Gerhard¹⁰,den Boer Monique L.¹¹,Pieters Rob¹¹,Horstmann Martin A.¹¹²,Janka-Schaub Gritta E.¹,Escherich Gabriele¹

Affiliation:

1. Clinic of Pediatric Hematology and Oncology, University Medical Centre, Hamburg-Eppendorf Hamburg, Germany;

2. Department of Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany;

3. Department of Pediatric Hematology and Oncology, Hospital Bielefeld, Bielefeld, Germany;

4. Department of Pediatric Hematology and Oncology, Hospital Bremen-Mitte, Bremen, Germany;

5. Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty Duesseldorf, Duesseldorf, Germany;

6. Department of Pediatric Hematology and Oncology, Helios Hospital, Krefeld, Germany;

7. Clinic of Pediatric Hematology and Oncology, University Medical Centre Leipzig, Leipzig, Germany;

8. Department of Pediatric Hematology/Oncology, University Hospital Mainz, Mainz, Germany;

9. Dr. von Hauner Children’s Hospital, Ludwig Maximilian University, Munich, Germany;

10. Department of Pediatric Hematology and Oncology, Helios Hospital, Wiesbaden, Germany;

11. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; and

12. Research Institute Children’s Cancer Centre, Hamburg, Germany

Abstract

Key Points Report of the long-term outcome of children with acute lymphoblastic leukemia upon risk-adapted therapy accrued in trial CoALL 07-03. Lack of correlation between in vitro and in vivo drug response as well as a lower predictive value of in vitro drug testing.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/22/3688/1543962/advancesadv2019000576.pdf

Reference30 articles.

1. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus;Schmiegelow;Lancet Oncol,2016

3. Cooperative Study Group for Childhood Acute Lymphoblastic Leukaemia (COALL): long-term results of trials 82,85,89,92 and 97;Escherich;Leukemia,2010

4. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97);Escherich;Haematologica,2011

5. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia;Graubner;Pediatr Blood Cancer,2008

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?;Leukemia;2024-06-06

2. The Clinical and Genetic Features of ETV6/RUNX1-like Acute Lymphoblastic Leukemia in Pediatric: A Multicenter Retrospective Study;2024-03-13

3. IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia;Biomedicines;2024-01-01

4. Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL;Journal of Clinical Oncology;2023-12-20

5. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials;Journal of Clinical Oncology;2023-11-10